Agency Business briefs

Share this article:
Rosetta is dropping “Wishbone” from the name of its healthcare unit, dubbed Rosetta Wishbone, following the network's May acquisition by Publicis. Rosetta acquired Wishbone in 2009. Unlike its Publicis siblings Razorfish and Digitas, which have been grouped together in the holding company's Vivaki unit, Rosetta will function as a standalone.  

inVentiv is aligning its Chandler Chicco and Chamberlain Communications units to create a global network of 12 companies and units focused on healthcare clients. High science-centric Chamberlain, with its staff of 60, will continue to operate as a separate business within the company's global structure. Chandler Chicco Company employees number some 350.

Michel Nakache has been brought on by McCann Healthcare Worldwide as EVP Europe. Nakache replaces McCann employee Mark Worman, who is returning to Australia. Nakache previously held the position of worldwide managing partner, chairman EMEA/APAC, and chairman global brands of Havas Worldwide Health and Euro RSCG Life. The new EVP has more than 30 years of experience in pharma and healthcare communications, on the client and agency sides.
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Features

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?